In June 2024, the FDA granted approval for blinatumomab to treat both adult and pediatric patients aged 1 month and older with CD19-positive, Ph-negative ALL during the consolidation phase, regardless of MRD status [25]. Here, CD19 is linked to acute lymphoblastic leukemia.